Financial - Capital Markets
Compare Stocks
5 / 10Stock Comparison
MKTX vs JPM vs ICE vs CME vs GS
Revenue, margins, valuation, and 5-year total return — side by side.
Banks - Diversified
Financial - Data & Stock Exchanges
Financial - Data & Stock Exchanges
Financial - Capital Markets
MKTX vs JPM vs ICE vs CME vs GS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Financial - Capital Markets | Banks - Diversified | Financial - Data & Stock Exchanges | Financial - Data & Stock Exchanges | Financial - Capital Markets |
| Market Cap | $5.43B | $825.89B | $88.45B | $104.07B | $287.62B |
| Revenue (TTM) | $849M | $270.79B | $12.64B | $6.52B | $126.85B |
| Net Income (TTM) | $310M | $58.03B | $3.30B | $4.24B | $16.67B |
| Gross Margin | 69.9% | 58.6% | 61.9% | 86.1% | 41.1% |
| Operating Margin | 41.2% | 27.7% | 38.7% | 64.9% | 14.5% |
| Forward P/E | 18.6x | 13.8x | 19.5x | 23.5x | 15.6x |
| Total Debt | $285M | $751.15B | $20.28B | $3.76B | $616.93B |
| Cash & Equiv. | $520M | $469.32B | $837M | $4.42B | $182.09B |
MKTX vs JPM vs ICE vs CME vs GS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| MarketAxess Holding… (MKTX) | 100 | 30.0 | -70.0% |
| JPMorgan Chase & Co. (JPM) | 100 | 314.8 | +214.8% |
| Intercontinental Ex… (ICE) | 100 | 160.6 | +60.6% |
| CME Group Inc. (CME) | 100 | 157.1 | +57.1% |
| The Goldman Sachs G… (GS) | 100 | 471.2 | +371.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MKTX vs JPM vs ICE vs CME vs GS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, MKTX doesn't own a clear edge in any measured category.
JPM ranks third and is worth considering specifically for income & stability and valuation efficiency.
- Dividend streak 14 yrs, beta 1.00, yield 1.7%
- PEG 1.06 vs MKTX's 3.03
- NIM 2.3% vs GS's 0.5%
- Lower P/E (13.8x vs 23.5x), PEG 1.06 vs 1.71
ICE is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.33, Low D/E 69.9%, current ratio 1.02x
- Beta 0.33, yield 1.2%, current ratio 1.02x
- Beta 0.33 vs GS's 1.47, lower leverage
CME carries the broadest edge in this set and is the clearest fit for quality and dividends.
- Efficiency ratio 0.2% vs JPM's 0.3% (lower = leaner)
- 3.8% yield, 6-year raise streak, vs JPM's 1.7%
- Efficiency ratio 0.2% vs JPM's 0.3%
GS is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 17.0%, EPS growth 77.3%
- 5.3% 10Y total return vs JPM's 461.3%
- 17.0% NII/revenue growth vs MKTX's 3.8%
- +70.6% vs MKTX's -31.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 17.0% NII/revenue growth vs MKTX's 3.8% | |
| Value | Lower P/E (13.8x vs 23.5x), PEG 1.06 vs 1.71 | |
| Quality / Margins | Efficiency ratio 0.2% vs JPM's 0.3% (lower = leaner) | |
| Stability / Safety | Beta 0.33 vs GS's 1.47, lower leverage | |
| Dividends | 3.8% yield, 6-year raise streak, vs JPM's 1.7% | |
| Momentum (1Y) | +70.6% vs MKTX's -31.7% | |
| Efficiency (ROA) | Efficiency ratio 0.2% vs JPM's 0.3% |
MKTX vs JPM vs ICE vs CME vs GS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MKTX vs JPM vs ICE vs CME vs GS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CME leads in 1 of 6 categories
JPM leads 1 • MKTX leads 1 • GS leads 1 • ICE leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
CME leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $270.8B annually — 318.9x MKTX's $849M. CME is the more profitable business, keeping 62.0% of every revenue dollar as net income compared to GS's 11.3%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $849M | $270.8B | $12.6B | $6.5B | $126.9B |
| EBITDAEarnings before interest/tax | $443M | $81.3B | $6.5B | $4.7B | $23.4B |
| Net IncomeAfter-tax profit | $310M | $58.0B | $3.3B | $4.2B | $16.7B |
| Free Cash FlowCash after capex | $236M | -$119.7B | $4.3B | $4.4B | $15.8B |
| Gross MarginGross profit ÷ Revenue | +69.9% | +58.6% | +61.9% | +86.1% | +41.1% |
| Operating MarginEBIT ÷ Revenue | +41.2% | +27.7% | +38.7% | +64.9% | +14.5% |
| Net MarginNet income ÷ Revenue | +29.0% | +21.6% | +26.1% | +62.0% | +11.3% |
| FCF MarginFCF ÷ Revenue | +44.0% | -15.5% | +33.9% | +64.3% | -12.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +4.5% | +16.0% | +23.1% | +21.4% | +45.8% |
Valuation Metrics
JPM leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 15.5x trailing earnings, JPM trades at a 43% valuation discount to ICE's 27.1x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 1.19x vs ICE's 3.05x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $5.4B | $825.9B | $88.4B | $104.1B | $287.6B |
| Enterprise ValueMkt cap + debt − cash | $5.2B | $1.11T | $107.9B | $103.4B | $722.5B |
| Trailing P/EPrice ÷ TTM EPS | 22.92x | 15.51x | 27.06x | 25.70x | 22.84x |
| Forward P/EPrice ÷ next-FY EPS est. | 18.63x | 13.79x | 19.48x | 23.49x | 15.64x |
| PEG RatioP/E ÷ EPS growth rate | 3.03x | 1.19x | 3.05x | 1.87x | 1.63x |
| EV / EBITDAEnterprise value multiple | 11.96x | 13.34x | 16.71x | 22.96x | 34.75x |
| Price / SalesMarket cap ÷ Revenue | 6.39x | 3.05x | 7.00x | 15.96x | 2.27x |
| Price / BookPrice ÷ Book value/share | 4.85x | 2.56x | 3.08x | 3.60x | 2.53x |
| Price / FCFMarket cap ÷ FCF | 14.51x | — | 20.62x | 24.82x | — |
Profitability & Efficiency
MKTX leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
MKTX delivers a 24.0% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $12 for ICE. CME carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to GS's 5.06x. On the Piotroski fundamental quality scale (0–9), ICE scores 9/9 vs GS's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +24.0% | +16.1% | +11.6% | +15.3% | +12.6% |
| ROA (TTM)Return on assets | +15.3% | +1.3% | +2.3% | +2.2% | +0.9% |
| ROICReturn on invested capital | +18.1% | +5.4% | +7.5% | +10.2% | +1.9% |
| ROCEReturn on capital employed | +25.4% | +8.2% | +9.5% | +3.6% | +3.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.25x | 2.18x | 0.70x | 0.13x | 5.06x |
| Net DebtTotal debt minus cash | -$235M | $281.8B | $19.4B | -$666M | $434.8B |
| Cash & Equiv.Liquid assets | $520M | $469.3B | $837M | $4.4B | $182.1B |
| Total DebtShort + long-term debt | $285M | $751.1B | $20.3B | $3.8B | $616.9B |
| Interest CoverageEBIT ÷ Interest expense | 168.60x | 0.74x | 6.53x | 41.55x | 0.31x |
Total Returns (Dividends Reinvested)
GS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GS five years ago would be worth $26,440 today (with dividends reinvested), compared to $3,822 for MKTX. Over the past 12 months, GS leads with a +70.6% total return vs MKTX's -31.7%. The 3-year compound annual growth rate (CAGR) favors GS at 43.5% vs MKTX's -18.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -14.1% | -5.0% | -2.1% | +9.1% | +1.8% |
| 1-Year ReturnPast 12 months | -31.7% | +25.2% | -10.4% | +4.6% | +70.6% |
| 3-Year ReturnCumulative with dividends | -46.0% | +134.6% | +50.8% | +71.4% | +195.2% |
| 5-Year ReturnCumulative with dividends | -61.8% | +104.3% | +43.4% | +64.5% | +164.4% |
| 10-Year ReturnCumulative with dividends | +38.3% | +461.3% | +225.3% | +284.9% | +534.3% |
| CAGR (3Y)Annualised 3-year return | -18.6% | +32.9% | +14.7% | +19.7% | +43.5% |
Risk & Volatility
Evenly matched — CME and GS each lead in 1 of 2 comparable metrics.
Risk & Volatility
CME is the less volatile stock with a -0.30 beta — it tends to amplify market swings less than GS's 1.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GS currently trades 94.0% from its 52-week high vs MKTX's 65.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.28x | 1.00x | 0.33x | -0.30x | 1.47x |
| 52-Week HighHighest price in past year | $232.84 | $337.25 | $189.35 | $329.16 | $984.70 |
| 52-Week LowLowest price in past year | $146.00 | $248.83 | $143.17 | $257.17 | $547.74 |
| % of 52W HighCurrent price vs 52-week peak | +65.6% | +90.8% | +82.5% | +87.1% | +94.0% |
| RSI (14)Momentum oscillator 0–100 | 26.8 | 59.4 | 38.8 | 44.1 | 59.5 |
| Avg Volume (50D)Average daily shares traded | 456K | 8.3M | 3.0M | 2.2M | 2.0M |
Analyst Outlook
Evenly matched — JPM and ICE and CME each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: MKTX as "Hold", JPM as "Buy", ICE as "Buy", CME as "Hold", GS as "Hold". Consensus price targets imply 28.1% upside for MKTX (target: $196) vs 7.6% for GS (target: $996). For income investors, CME offers the higher dividend yield at 3.81% vs ICE's 1.24%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | $195.60 | $338.78 | $195.71 | $320.25 | $995.89 |
| # AnalystsCovering analysts | 23 | 61 | 36 | 35 | 55 |
| Dividend YieldAnnual dividend ÷ price | +2.0% | +1.7% | +1.2% | +3.8% | +1.5% |
| Dividend StreakConsecutive years of raises | 12 | 14 | 14 | 6 | 12 |
| Dividend / ShareAnnual DPS | $3.13 | $5.13 | $1.93 | $10.92 | $13.48 |
| Buyback YieldShare repurchases ÷ mkt cap | +7.7% | +3.5% | +1.6% | +0.3% | +3.5% |
CME leads in 1 of 6 categories (Income & Cash Flow). JPM leads in 1 (Valuation Metrics). 2 tied.
MKTX vs JPM vs ICE vs CME vs GS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MKTX or JPM or ICE or CME or GS a better buy right now?
For growth investors, The Goldman Sachs Group, Inc.
(GS) is the stronger pick with 17. 0% revenue growth year-over-year, versus 3. 8% for MarketAxess Holdings Inc. (MKTX). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 5x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MKTX or JPM or ICE or CME or GS?
On trailing P/E, JPMorgan Chase & Co.
(JPM) is the cheapest at 15. 5x versus Intercontinental Exchange, Inc. at 27. 1x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 13. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 1. 06x versus MarketAxess Holdings Inc. 's 3. 03x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — MKTX or JPM or ICE or CME or GS?
Over the past 5 years, The Goldman Sachs Group, Inc.
(GS) delivered a total return of +164. 4%, compared to -61. 8% for MarketAxess Holdings Inc. (MKTX). Over 10 years, the gap is even starker: GS returned +534. 3% versus MKTX's +38. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MKTX or JPM or ICE or CME or GS?
By beta (market sensitivity over 5 years), CME Group Inc.
(CME) is the lower-risk stock at -0. 30β versus The Goldman Sachs Group, Inc. 's 1. 47β — meaning GS is approximately -582% more volatile than CME relative to the S&P 500. On balance sheet safety, CME Group Inc. (CME) carries a lower debt/equity ratio of 13% versus 5% for The Goldman Sachs Group, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MKTX or JPM or ICE or CME or GS?
By revenue growth (latest reported year), The Goldman Sachs Group, Inc.
(GS) is pulling ahead at 17. 0% versus 3. 8% for MarketAxess Holdings Inc. (MKTX). On earnings-per-share growth, the picture is similar: The Goldman Sachs Group, Inc. grew EPS 77. 3% year-over-year, compared to -8. 5% for MarketAxess Holdings Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MKTX or JPM or ICE or CME or GS?
CME Group Inc.
(CME) is the more profitable company, earning 62. 0% net margin versus 11. 3% for The Goldman Sachs Group, Inc. — meaning it keeps 62. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CME leads at 64. 9% versus 14. 5% for GS. At the gross margin level — before operating expenses — CME leads at 86. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MKTX or JPM or ICE or CME or GS more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 1. 06x versus MarketAxess Holdings Inc. 's 3. 03x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 13. 8x forward P/E versus 23. 5x for CME Group Inc. — 9. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MKTX: 28. 1% to $195. 60.
08Which pays a better dividend — MKTX or JPM or ICE or CME or GS?
All stocks in this comparison pay dividends.
CME Group Inc. (CME) offers the highest yield at 3. 8%, versus 1. 2% for Intercontinental Exchange, Inc. (ICE).
09Is MKTX or JPM or ICE or CME or GS better for a retirement portfolio?
For long-horizon retirement investors, CME Group Inc.
(CME) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 30), 3. 8% yield, +284. 9% 10Y return). Both have compounded well over 10 years (CME: +284. 9%, GS: +534. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MKTX and JPM and ICE and CME and GS?
Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MKTX is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; ICE is a mid-cap quality compounder stock; CME is a mid-cap income-oriented stock; GS is a large-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.